LGALS3BP and metabolic dysfunction-associated steatotic liver disease: LGALS3BP, which was up‐regulated in NAFLD and T2D, is a candidate biomarker for hepatitis C‐related fibrosis and cirrhosis (Cheung et al, 2010).